Meitheal

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 3 drugs with upcoming expirations

Activity

Key Events

Oct 22, 2025FDAMonurol — CONTEPO

Aug 15, 2025FDACyklx — CYKLX

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

4 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Zioptan2 patentsMay 28, 2029 Monurol2 patentsOct 12, 2034 MonurolJan 30, 2039 Cyklx3 patentsMar 27, 2039

Regulatory

Regulatory Timeline

19961 event

FDAMay 28

Hycamtin — HYCAMTIN

Application NDA020671 (NDA)

20071 event

FDAOct 11

Hycamtin — HYCAMTIN

Application NDA020981 (NDA)

20112 events

FDAFeb 25

Hycamtin — TOPOTECAN

Application NDA200199 (NDA)

FDAFeb 2

Hycamtin — TOPOTECAN HYDROCHLORIDE

Application NDA200582 (NDA)

20122 events

FDADec 20

Hycamtin — TOPOTECAN HYDROCHLORIDE

Application NDA022453 (NDA)

FDAFeb 10

Zioptan — ZIOPTAN

Application NDA202514 (NDA)

20252 events

FDAOct 22

Monurol — CONTEPO

Application NDA212271 (NDA)

FDAAug 15

Cyklx — CYKLX

Application NDA218643 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)